| abstract |
The present invention relates to anti-HER2 binding molecules (eg, antibodies and antigen-binding fragments thereof) that bind to the extracellular domain of the HER2 receptor, derived HER2 binding molecules (eg, bispecific anti-HER2 antibodies), and antibody- It relates to drug conjugates (ADC). Also provided are pharmaceutical formulations comprising the disclosed compositions and methods for treating diseases associated with HER2-mediated signaling. [Selection figure] None |